文献速递青光眼

高眼压症治疗研究中青光眼发病的多基因风险评分

Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

该研究是对高眼压症治疗研究的事后分析,纳入1009例参与者,随访至2008年12月。结果显示,多基因风险评分(PRS)较高与原发性开角型青光眼(POAG)发病风险增加相关,每升高1个标准差的风险比为1.25(95%CI 1.13-1.44),将PRS加入预测模型可改善预测能力(C指数0.77 vs 0.75,P<.001)。

要点

  • 在高眼压症患者中,较高的PRS与POAG发病风险增加相关(每1-SD的HR为1.25,95%CI 1.13-1.44)。
  • PRS最高十分位组的POAG转化率为21.81%,最低十分位组为9.52%。
  • 将PRS加入预测模型后C指数从0.75提高至0.77(P<.001)。

核心结论

  • 较高的PRS与高眼压症患者POAG风险增加相关。
  • 将PRS纳入模型可改善对POAG发病的预测。

研究设计与样本

  • 该研究为高眼压症治疗研究的事后分析,数据来自美国22个中心,平均随访14.0(6.9)年。
  • 1636例参与者于1994年2月至2008年12月随访,其中1077例参与辅助遗传学研究,1009例符合本分析条件。
  • PRS使用跨祖先POAG荟萃分析的汇总统计量计算,权重基于英国生物银行449186例跨祖先参与者的8813496个变异训练。
  • 1994年2月至2002年6月,参与者随机接受局部降眼压药物或密切观察;2002年6月后两组均接受药物治疗。

主要发现

  • 350例POAG转化者的平均PRS为0.24(0.95),显著高于659例未转化者的-0.12(1.00)(P<.001)。
  • PRS每升高一个十分位,POAG风险增加1.36%(95%CI 1.08-1.64);转化率从最低十分位的9.52%(95%CI 7.09-11.95)升至最高十分位的21.81%(95%CI 19.37-24.25)。
  • 在延迟治疗随机组中,PRS每升高一个十分位,诊断年龄提前0.52年(95%CI 0.01-1.03)(P=.047);早期治疗组中未见PRS与诊断年龄的显著线性关联。
  • 加入PRS作为协变量的预测模型C指数为0.77,显著优于高眼压症治疗研究基线模型的0.75(P<.001)。
  • PRS每升高1个标准差,POAG发病的平均风险比为1.25(95%CI 1.13-1.44)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Primary open-angle glaucoma (POAG) is a highly heritable disease, with 127 identified risk loci to date. Polygenic risk score (PRS) may provide a clinically useful measure of aggregate genetic burden and improve patient risk stratification. OBJECTIVE: To assess whether a PRS improves prediction of POAG onset in patients with ocular hypertension. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Ocular Hypertension Treatment Study. Data were collected from 22 US sites with a mean (SD) follow-up of 14.0 (6.9) years. A total of 1636 participants were followed up from February 1994 to December 2008; 1077 participants were enrolled in an ancillary genetics study, of which 1009 met criteria for this analysis. PRS was calculated using summary statistics from the largest cross-ancestry POAG meta-analysis, with weights trained using 8 813 496 variants from 449 186 cross-ancestry participants in the UK Biobank. Data were analyzed from July 2022 to December 2023. EXPOSURES: From February 1994 to June 2002, participants were randomized to either topical intraocular pressure-lowering medication or close observation. After June 2002, both groups received medication. MAIN OUTCOMES AND MEASURES: Outcome measures were hazard ratios for POAG onset. Concordance index and time-dependent areas under the receiver operating characteristic curve were used to compare the predictive performance of multivariable Cox proportional hazards models. RESULTS: Of 1009 included participants, 562 (55.7%) were female, and the mean (SD) age was 55.9 (9.3) years. The mean (SD) PRS was significantly higher for 350 POAG converters (0.24 [0.95]) compared with 659 nonconverters (-0.12 [1.00]) (P < .001). POAG risk increased 1.36% (95% CI, 1.08-1.64) with each higher PRS decile, with conversion ranging from 9.52% (95% CI, 7.09-11.95) in the lowest PRS decile to 21.81% (95% CI, 19.37-24.25) in the highest decile. Comparison of low-risk and high-risk PRS tertiles showed a 2.0-fold increase in 20-year POAG risk for participants of European and African ancestries. In the subgroup randomized to delayed treatment, each increase in PRS decile was associated with a 0.52-year (95% CI, 0.01-1.03) decrease in age at diagnosis (P = .047). No significant linear association between PRS and age at POAG diagnosis was present in the early treatment group. Prediction models significantly improved with the addition of PRS as a covariate (C index = 0.77) compared with the Ocular Hypertension Treatment Study baseline model (C index = 0.75) (P < .001). Each 1-SD higher PRS conferred a mean hazard ratio of 1.25 (95% CI, 1.13-1.44) for POAG onset. CONCLUSIONS AND RELEVANCE: Higher PRS was associated with increased risk for POAG in patients with ocular hypertension. The inclusion of a PRS improved the prediction of POAG onset. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00000125.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Singh RK, Zhao Y, Elze T, et al. Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study. JAMA Ophthalmol. 2024. PMID: 38483402. doi:10.1001/jamaophthalmol.2024.0151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。